Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

Research and Innovation Action · Running

4U-PI Ultrafast, Ultrashort, Ultrahigh-peak-flux, and Ultrahigh-dose-rate Particle Sources Driven by High-intensity Lasers

Coordinator
Extreme Light Infrastructure Eric, Czechia
Runs
1 September 2026 to 31 August 2030
Status
Running
EU funding
€10.1m
Total cost
€10.1m
Partners
12 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101290656

What the project is doing

In the project's own words, from its summary on CORDIS.

4U-PI: Ultrafast, Ultrashort, Ultrahigh-peak-flux, and Ultrahigh-dose-rate Particle sources driven by high-Intensity lasers, will advance Europe’s leadership in laser–plasma acceleration and its translation to biomedical and industrial impact. 4U-PI will develop and exploit ultrashort, ultrahigh-dose-rate ion and neutron bunches as novel radiation tools for users, setting new benchmarks in temporal precision and particle flux.

By building on the plasma accelerator roadmap by Albert et al. (NJP 2021), 4U-PI will pioneer high-repetition-rate ion sources, hybrid acceleration schemes, compact beam transport, and advanced diagnostics, pushing the field toward user-ready platforms. In addition, it implements the biomedical roadmap by Hideghety et al. (EPJP 2025) by enabling breakthrough studies in ultrafast radiation biology, FLASH and microbeam therapy, and isotope production, supported by standardized dosimetry and radiobiology protocols.

The consortium unites 12 partners from 6 countries led by Europe’s flagship infrastructures (ELI ERIC (Beamlines, ALPS), ELI-NP, and FAIR)—and large national infrastructures (GSI, CLF-UKRI, HZDR, ATOMKI) as the backbone for high-impact user experiments. Clinical, industrial and cross sectoral partners (PTC, MIRROTRON, Focused Energy, EIT Manufacturing) ensure translation into medicine, industry, and technology. Multi-modal imaging with laser-driven sources will extend the impact to industry and security applications, while AI/ML-enabled diagnostics will ensure reproducibility and open path to autonomous operation.

Supported by 9 stakeholders 4U-PI is extending impact to clinics, industry, and innovation. Through this dual alignment with technological&biomedical roadmaps, 4U-PI will validate key exploitable results ranging from ultrafast beamlines to imaging and AI solutions. The outcomes will accelerate clinical translation, foster industrial competitiveness, and reinforce Europe’s strategic autonomy in ultrafast science&innovation.

Topics

Who is involved

OrganisationCityCountryRole
Extreme Light Infrastructure EricDolni BrezanyCzechiaCoordinator
Proton Therapy Center Czech S.r.o.PrahaCzechiaParticipant
Facility for Antiproton and Ion Research in Europe GmbHDarmstadtGermanyParticipant
Focused Energy GmbHDarmstadtGermanyParticipant
Gsi Helmholtzzentrum Fur Schwerionenforschung GmbHDarmstadtGermanyParticipant
Helmholtz-Zentrum Dresden-Rossendorf eVDresdenGermanyParticipant
Eli-Hu Kutatasi Es Fejlesztesi Nonprofit Kozhasznu Korlatolt Felelossegu TarsasagSzegedHungaryThird party
HUN-REN Atommagkutato IntezetDebrecenHungaryParticipant
Mirrotron Muszaki Fejleszto Es Szolgaltato KftBudapestHungaryParticipant
Eit Manufacturing South SRLMilanoItalyParticipant
Institutul National De Cercetare-Dezvoltare Pentru Fizica Si Inginerie Nucleara-Horia HulubeiMagureleRomaniaParticipant
United Kingdom Research and InnovationSwindonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI